In 1974, Matthew Emmens began his first post-college job as a Merck sales rep. Of his 600 peers, only one was a woman. So, for Emmens, CEO of Shire Pharmaceuticals, to be named Healthcare Businesswomen's Association (HBA) Honorable Mentor for 2006 -- in recognition of his long-term support for the advancement of women in the industry -- this is a telling memory. Emmens feels his biggest success is having put together an experienced team that has refocused the company in a changed environment to the point where they feel, and the equity markets feel, that they are extremely well positioned to be competitive. The assistance Emmens has given his peers over the years is less debatable.
Chairman and Chief Executive Officer Celphalon, Inc. Richard T. Clark Chairman, President, and Chief Executive Officer Merck & Co., Inc. Matthew Emmens Chief Executive Officer Shire Pharmaceuticals Jean-Pierre Gamier Chief Executive Officer GlaxoSmithKline Bernard Poussot President and Chief Executive Officer Wyeth Tony Zook President and Chief Executive Officer AstraZeneca Pharmaceuticals LP, U.S. Christine A. Poon Vice Chairman, Board of Directors Johnson & Johnson As the president and CEO of the Biotechnology Industry Organization (BIO), it is my privilege to represent an industry that is saving and improving the lives, health, and well-being of billions of people around the world. Another key to success has been the solid support from policymakers, including major public in...
MM&M Awards 2006 finalists' photographs depict members of their panel of 43 seasoned industry executives reviewing and scoring more than 600 entries to this year's program. From Shire CEO Matthew Emmens to McCann chief Richard Nordstrom to Merck marketing director Charlotte McKines, and 40 others, each judge gave up a day of their valuable time to work tirelessly and diligently, ensuring that every submission got a fair crack at the whip. They go to great pains to bring together the best blend of talent, experience and insight they can find from all walks of the industry. They do not score any entries ourselves; they merely do the math at the end. The judges' dedication and commitment ensures that their processes are fair, independent and authoritative. The finalist for each of the ...
Shire has amassed a 560-person sales force to launch its new ADHD drug Vyvanse. The Vyvanse sales force is comprised of members who have experience selling other Shire ADHD products. Shire's CEO Matthew Emmens said he is hopeful the drug will be able to capture 50% market share by early next decade. Shire is expected to sell Vyvanse at $3.40 a day, around the same price as Adderall XR. Vyvanse's selling point is that the drug is less open to abuse because it cannot be metabolized until it reaches the stomach.
...Matthew Emmens, Chairman, President and Chief Executive Of...
... a better chance of a viral cure," said Matthew Emmens, Chairman, President and Chief Executive Of...
... our strong collaboration with them," said Matthew Emmens, Chairman, President and Chief Executive Of...
...2006 JUDGES: Standing L-R: Matthew Emmens, Peter Labadie, David Graham, Trip Hosmer, ...
...Matthew Emmens, Chairman, President and Chief Executive Of...
... to people with hepatitis C," said Matthew Emmens, Chairman, President and Chief Executive Of...
ver las páginas en versión mobile | web
ver las páginas en versión mobile | web
© Copyright 2012, vLex. All Rights Reserved.
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Other interesting searches:
certificate format health of | Steve Ruda | Shanghai Datun Energy Resources Co Ltd | Mustek Systems Inc. | Spring Valley | quaestiones giurisprudenza | Hulluch | Perito de parte | reversibilita' rendita inail | sistema penal en mexico
